DE60115432T2 - Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen - Google Patents

Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen Download PDF

Info

Publication number
DE60115432T2
DE60115432T2 DE2001615432 DE60115432T DE60115432T2 DE 60115432 T2 DE60115432 T2 DE 60115432T2 DE 2001615432 DE2001615432 DE 2001615432 DE 60115432 T DE60115432 T DE 60115432T DE 60115432 T2 DE60115432 T2 DE 60115432T2
Authority
DE
Germany
Prior art keywords
apoptotic
cells
use according
bodies
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE2001615432
Other languages
German (de)
English (en)
Other versions
DE60115432D1 (de
Inventor
Daniel Sauder
Arkady Mandel
Anthony E. Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of DE60115432D1 publication Critical patent/DE60115432D1/de
Application granted granted Critical
Publication of DE60115432T2 publication Critical patent/DE60115432T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
DE2001615432 2000-05-25 2001-05-25 Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen Expired - Fee Related DE60115432T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2309518 2000-05-25
CA 2309518 CA2309518A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
PCT/CA2001/000758 WO2001089536A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Publications (2)

Publication Number Publication Date
DE60115432D1 DE60115432D1 (de) 2006-01-05
DE60115432T2 true DE60115432T2 (de) 2006-08-24

Family

ID=4166254

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2001615432 Expired - Fee Related DE60115432T2 (de) 2000-05-25 2001-05-25 Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen

Country Status (11)

Country Link
US (1) US20020051771A1 (enExample)
EP (2) EP1669081A1 (enExample)
JP (1) JP2003534281A (enExample)
AT (1) ATE311191T1 (enExample)
AU (1) AU2001261986A1 (enExample)
CA (1) CA2309518A1 (enExample)
DE (1) DE60115432T2 (enExample)
DK (1) DK1289534T3 (enExample)
ES (1) ES2254424T3 (enExample)
TW (1) TWI249404B (enExample)
WO (1) WO2001089536A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
WO2003015850A1 (en) * 2001-08-13 2003-02-27 Edelson Richard Leslie Method for inducing selectively suppressed immune response
EP1469733A4 (en) * 2001-11-29 2008-07-23 Therakos Inc METHOD FOR PRE-TREATING A PATIENT WITH EXTRACORPORAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
JP6483023B2 (ja) * 2012-12-06 2019-03-13 エンリヴェックス セラピューティクス リミテッド 治療用アポトーシス細胞調製物、その製造方法及びその使用
US11512289B2 (en) * 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA3014885A1 (en) * 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
WO2023209709A1 (en) * 2022-04-27 2023-11-02 Enlivex Therapeutics Rdo Ltd Apoptotic cell - chemotherapy combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
EP1469733A4 (en) * 2001-11-29 2008-07-23 Therakos Inc METHOD FOR PRE-TREATING A PATIENT WITH EXTRACORPORAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS

Also Published As

Publication number Publication date
AU2001261986A1 (en) 2001-12-03
WO2001089536A2 (en) 2001-11-29
WO2001089536A3 (en) 2002-08-01
ES2254424T3 (es) 2006-06-16
TWI249404B (en) 2006-02-21
CA2309518A1 (en) 2001-11-25
DK1289534T3 (da) 2006-03-20
HK1055079A1 (en) 2003-12-24
EP1289534A2 (en) 2003-03-12
EP1669081A1 (en) 2006-06-14
DE60115432D1 (de) 2006-01-05
US20020051771A1 (en) 2002-05-02
EP1289534B1 (en) 2005-11-30
JP2003534281A (ja) 2003-11-18
ATE311191T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DE60115432T2 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
US20080131416A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
DE69833333T2 (de) Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
DE2635065A1 (de) Verfahren zur halbkontinuierlichen behandlung von gesamtblut
US20080063631A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
DE3104815C2 (de) Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe
DE2645993A1 (de) Mittel gegen myeloische leukaemie und sein herstellungsverfahren
Weston et al. Release of acetylcholinesterase in the rat nigrostriatal pathway: relation to receptor activation and firing rate
Toledo‐Piza et al. Proliferation of fibroblasts and endothelial cells is enhanced by treatment with Phyllocaulis boraceiensis mucus
DE60211721T2 (de) Apoptose-imitierende natürliche vesikel und deren verwendung zur medizinischen behandlung
DE68903065T2 (de) Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien.
CA2409960A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
HK1055079B (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
HK1093428A (en) Apoptotic entities for use in treatment of t-cell-mediated und inflammatory disorders
Abdulgani et al. Effect of Musa paradisiaca L. var. Kayu Unripe Fruit Ethanol Extract on Leukocyte Differentiation and Skin Histology of Mus musculus
Nwakanma Effect of Ethanolic Leaf Extract of Sida Corymbosa (Wire Weed) on Alloxan Induced Pancreatic Damage in Adult Male Wistar Rats
CA2409992A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
US20070298020A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
HK1055080B (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
EP1121146B1 (de) Beeinflussung von hyperaktiven t-zellen durch proteolytische enzyme
DE19726244C2 (de) Verwendung proteolytischer Enzyme und Rutosid zur Vorbeugung bzw. Behandlung der Transplantatabstoßung
DE2406084A1 (de) Immunodepressives anti-humanlymphozytenserum und verfahren zu dessen herstellung
EP0918538A1 (de) Verwendung proteolytischer enzyme zur behandlung von uveitis
EP0299429A2 (de) Verfahren zur Herstellung eines Präparates auf Grundlage von Immunabwehrzellen aus der Wharton-Sulze

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee